Related Parties	12 Months Ended
Dec. 31, 2015
Related Parties.
Related Parties	20. Related Parties As discussed in Note 3, in September 2014, the Company entered into an Exclusive License and Collaboration Agreement (the “Livzon Collaboration Agreement”) with Livzon Mabpharm Inc. (“Livzon”) for the global development and commercialization of certain antibodies or related biological compounds, including the Company’s BOW015, a biosimilar version of infliximab. In September 2015, the Company entered into a New Collaboration Compound Supplement with Livzon to add BOW070, a biosimilar version of tocilizumab, as a compound to be governed by the Livzon Collaboration Agreement. As of December 31, 2015, Livzon owned approximately 6.4% of the Company’s issued and outstanding common stock. As discussed in Note 3, in September 2014 and October 2014, the Company entered into a series of amendments (collectively, the “amendments”) to that certain Revenue and Negotiation Rights Agreement between the Company and Moksha8 Pharmaceuticals, Inc. (“Moksha8”), dated as of December 31, 2010 (the “Moksha8 Revenue Agreement”). Moksha8 is owned in part by Montreux Equity Partners and TPG Capital, which are also shareholders of the Company. As of December 31, 2015, Montreux Equity Partners owned approximately 1% of the Company’s issued and outstanding common stock and TPG Capital owned approximately 9% of the Company’s issued and outstanding common stock.

Related Parties

12 Months Ended

Dec. 31, 2015

20. Related Parties

As discussed in Note 3, in September 2014, the Company entered into an Exclusive License and Collaboration Agreement (the “Livzon Collaboration Agreement”) with Livzon Mabpharm Inc. (“Livzon”) for the global development and commercialization of certain antibodies or related biological compounds, including the Company’s BOW015, a biosimilar version of infliximab. In September 2015, the Company entered into a New Collaboration Compound Supplement with Livzon to add BOW070, a biosimilar version of tocilizumab, as a compound to be governed by the Livzon Collaboration Agreement. As of December 31, 2015, Livzon owned approximately 6.4% of the Company’s issued and outstanding common stock.

As discussed in Note 3, in September 2014 and October 2014, the Company entered into a series of amendments (collectively, the “amendments”) to that certain Revenue and Negotiation Rights Agreement between the Company and Moksha8 Pharmaceuticals, Inc. (“Moksha8”), dated as of December 31, 2010 (the “Moksha8 Revenue Agreement”). Moksha8 is owned in part by Montreux Equity Partners and TPG Capital, which are also shareholders of the Company. As of December 31, 2015, Montreux Equity Partners owned approximately 1% of the Company’s issued and outstanding common stock and TPG Capital owned approximately 9% of the Company’s issued and outstanding common stock.